1688-0420

S1688-04202024000101402

10.29277/cardio.39.1.7

Mexico

00 00 2024

39 1

2020 9 2 2

227-44

2015 20 1 1

13-24

2018 24 9 9

550-2

and the EF-HF Group 2018 6 4 4

273-85

de la Espriella R.Santas E.Zegri I.Górriz J.Cobo M.Núñez J

2022 42 2 2

145-62

2019 21 2 2

137-55

O'Connor C.Metra M 2018 258

185-91

2022 150 4 4

493-504

Fiaccadori E management of congestion and diuretic resistance in heart failure 2016 2 1 1

e73-87

2020 7 6 6

3830-40

2018 33 3 3

462-73

2019 6 6 6

1222-5

ICA-SEMES group 2022 222 6 6

321-31

2022 28 7 7

1217-21

2016 22 9 9

713-22

CHANCE-HF Investigators 2016 4 11 11

833-43

O'Connor C.Sopko G.Hasselblad V.Califf R.Stevenson L 2001 141 4 4

528-35

CHAMPION Trial Investigators 2017 70 15 15

1875-86

et al 'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor 2021 8 6 6

4444-53

2017 69 25 25

3042-51

2014 16 5 5

471-82

2016 9 8 8

2021 77 6 6

709-12

2019 2 3 3

1-8

2021 21 6 6

595-608

NHLBI Heart Failure Clinical Research Network 2011 364 9 9

797-805

2020 109 4 4

417-25

CLOROTIC trial investigators 2023 44 5 5

411-21

National Heart Lung and Blood Institute Heart Failure Clinical Research Network 2017 2 9 9

950-8

ADVOR Study Group 2022 387 13 13

1185-95

2022 28 3 3

568-74

2022 9 1 1

155-63

2019 21 3 3

342-4

MEMS-HF Investigators 2020 22 10 10

1891-901

2020 8 3 3

199-208

2014 20 5 5

295-301

2021 21 3 3

331-47

2011 342 1 1

27-37

2023 13 1 1

140

2017 69 11 11

1399-406

2008 6 10 10

1331-8

2014 172 1 1

115-21

2014 20 1 1

9-17

UNLOAD Trial Investigators 2007 49 6 6

675-83

2023 10 4 4

2290-7

2019 322 23 23

2292-302

2021 77 6 6

695-708

2009 30 13 13

1666-73

NHLBI Heart Failure Network Steering Committee and Investigators 2013 6 2 2

240-5

2023 12 3 3

773